Table 1.

Descriptive data on anthropometry, smoking habits, COVID-19 related medical history and clinical characteristics of the sample. Values are mean (SD) and n (%).

	Muscle Training Groups
	Inspiratory	Inspiratorysham	Respiratory	Respiratorysham
	(n = 22)	(n = 22)	(n = 22)	(n = 22)
Anthropometric characteristics
Age (years)	48.9 (8.3)	45.3 (12.8)	46.5 (9.6)	45 (10.2)
Sex (female)	17 (77 %)	16 (73 %)	14 (64 %)	16 (73 %)
Height (m)	1.6 (0.1)	1.7 (0.1)	1.7 (0.1)	1.7 (0.1)
Weight (Kg)	71.7 (15.5)	77.2 (17)	76 (17.6)	78.1 (19.1)
Body mass index (Kg/m2)	26.6 (6.6)	27.1 (5.1)	27 (5.2)	27.1 (6)
Smoking habits
Non-smoker	10 (45 %)	11 (50 %)	11 (50 %)	13 (59 %)
Ex-smoker	6 (27 %)	8 (36 %)	6 (27 %)	7 (32 %)
Smoker	6 (27 %)	3 (14 %)	5 (23 %)	2 (9 %)
Cumulative amount of smoking (in pack-years)	8.3 (15.5)	6.8 (12.7)	4.6 (7.4)	5.8 (12.9)
COVID-19 related medical history
Time from COVID-19 diagnosis (days)	349 (86)	334 (107)	364 (67)	356 (95)
Pneumonia	8 (36 %)	9 (41 %)	9 (41 %)	9 (41 %)
Hospital admission	8 (36 %)	7 (32 %)	6 (27 %)	7 (32 %)
Intensive care unit admission	1 (5 %)	0 (0 %)	2 (9 %)	2 (9 %)
Clinical characteristics
Dyspnoea	22 (100 %)	22 (100 %)	22 (100 %)	22 (100 %)
Fatigue	22 (100 %)	22 (100 %)	22 (100 %)	22 (100 %)
Chest pain	13 (59 %)	12 (55 %)	12 (55 %)	15 (68 %)
Joint pain	8 (36 %)	8 (36 %)	9 (41 %)	7 (32 %)
Muscle pain	7 (32 %)	8 (36 %)	8 (36 %)	8 (36 %)
Headache	10 (45 %)	6 (27 %)	8 (36 %)	9 (41 %)
Brain fog	13 (59 %)	10 (45 %)	13 (59 %)	13 (59 %)
Insomnia	11 (50 %)	8 (36 %)	8 (36 %)	8 (36 %)
Tachycardia	6 (27 %)	7 (32 %)	6 (27 %)	5 (23 %)
Tingling	7 (32 %)	7 (32 %)	6 (27 %)	4 (18 %)
Anosmia	3 (14 %)	3 (14 %)	1 (5 %)	3 (14 %)
Dysphonia	2 (9 %)	1 (5 %)	1 (5 %)	4 (18 %)
Medications
Corticosteroids	1 (5%)	2 (9%)	1 (5%)	1 (5%)
Muscle relaxant	1 (5%)	2 (9%)	1 (5%)	3 (14%)
Sedatives	4 (18%)	2 (9%)	2 (9%)	4 (18%)
Analgesics	5 (23%)	4 (18%)	3 (14%)	3 (14%)
Antidepressants	1 (5%)	2 (9%)	2 (9%)	2 (9%)
Antiepileptics	-	-	2 (9%)	1 (5%)